Skip navigation

Critical Updates on Pressing Issues Including Drug Pricing Oversight, Value-Based Frameworks and State Pricing Transparency

November 7-8, 2018
  • Baltimore, MD
Critical, Breaking News Impacting Manufacturers in the Government and Drug Pricing Industry: HHS Set to Implement Long Delayed 340B Final Rule in January
CMS Finalizes Site Neutral Payment Rule

Bio/pharma manufacturers continue to grapple with a rapidly evolving healthcare landscape and heavy government scrutiny and oversight on price reporting. With the advent of Trump’s America First Blueprint, the outlook is that the scrutiny will continue and pressures to curb drug costs will rise. CBI’s Drug Pricing Policy and Reporting provides an in-depth look at potential areas of reform and offer operational strategies around value-based frameworks, state pricing requirements, 340B and commercial contracting.

Benefit From Operational Strategies and Discussion on Topics Including:

  • Scenario-planning for potential price reporting implications
  • Evolving PBM business model and impacts to pricing
  • Litigation and investigations impacting government contracting and pricing
  • The current state of the 340B regulatory outlook
  • 340B analytics and duplicate discount prevention
  • Value-based contracting and government pricing considerations
  • Strategies to ensure drug categorization accuracy in DDR
  • Updates within the state drug pricing transparency landscape
  • The impact of the changing customer landscape on pricing and reporting

Attendee Acclaim From CBI’s Government Pricing Series:

The conference was informative and a great opportunity to network with industry peers.

Excellent conference with best in class speakers!

Very informative, good discussion, great networking!

The content was great.

Excellent content and subject matter experts along with great networking and benchmarking opportunities for networking.

Up to the minute updates, informative and great speakers.